Press releasePRNewswire
Redhill Biopharma
RDHL · NASDAQ
$0.5073−$0.0023 (−0.45%)TodayMarket closed ·
Prev close $0.5096
Latest news
- Press releaseGlobe Newswire
Small Caps Test Their 200-Day Line as Yields Grind Higher and Earnings Season Stirs
- Press releasePRNewswire
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet
- Press releasePRNewswire
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
- Press releasePRNewswire
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
- NewsVandana Singh
Redhill Biopharma Stock Doubles In One Session — Here's Why
- News
Market-Moving News for August 31st
- Press releasePRNewswire
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
- Press releasePRNewswire
RedHill Biopharma Announces Up To $19.4 Million Private Placement
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
- Press releasePRNewswire
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
- News
RedHill Biopharma Engages WHO Solidarity Platform And Pharma Partners To Advance Opaganib As Oral Host Directed Therapy For Ebola Virus Disease Amid Bundibugyo Outbreak Showing Preclinical Filovirus Activity And Prior Phase 3 Antiviral Results
- Press releasePRNewswire
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
- Press releasePRNewswire
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
- News
Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY
- Press releasePRNewswire
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
- Press releasePRNewswire
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
- Press releasePRNewswire
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
- Press releasePRNewswire
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Press releasePRNewswire
Joint U.S. Commercialization of RedHill's Talicia® Commences
- NewsVandana Singh
What's Going On With Redhill Biopharma Stock On Tuesday?
- NewsAvi Kapoor
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
- News
Market-Moving News for January 5th
- Press releasePRNewswire
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
- Press releasePRNewswire
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
- Press releasePRNewswire
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.